Can the course of multiple sclerosis be modified?

Practical Neurology

Volumn 5, Issue 5, 2005, Pages 278-287

  Coles, Alasdair ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE;

ANTIINFLAMMATORY ACTIVITY; CANCER; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; META ANALYSIS; MULTIPLE SCLEROSIS; PRESCRIPTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 27844448644     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1474-7766.2005.00332.x     Document Type: Review

References (44)

1. Bechtold DA, Kapoor R & Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Annals of Neurology, 55, 607-16
2. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. (2003) The longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl Journal of Medy, 346, 158-64.
3. Chard DT, Brex PA Ciccarelli O et al. (2003) The longitudinal relation between brain lesion load and atrophy in multiples sclerosis: a 14 year follow up study. Journal of Neurological Neurosurg Psychiatry, 74, 1551-4
4. Coles A, Cox AL, Le Page E et al. (2005) The window of therpautic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy in relapsing-remitting and secondary progressive disease. Journal of Neurology in press.
5. Coles AJ, Wing M, Molyneux P et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology, 46, 296-304
6. Comi G, Filippi M, Barkhof F et al. (2001) Effect of early interferon treatment on conversion ot definite multiple sclerosis: a randomised study. Lancet, 357, 1576-82
7. Confavreux C, Saddier P, Grimaud J, Moreau T, Adeleine P & Aimard G (1996) Risk of cancer from azasthioprine therapy in multiple sclerosis: a case- control study. Neurology, 46, 1907-12
8. Confavreux C, Vukusic S & Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain, 126, 770-82
9. Confavreux C, Vukusic S, Moreau T & Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. New England Journal of Medy, 343, 1430,-8
10. Duquette P, Despault L, Knobler RL et al. (1995) Interferon beta- 1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology, 45, 1277-85
11. European study Group on beta IFN & in secondary progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta- 1b in treatment of secondary progressive multiple sclerosis. Lancet, 352, 1491-7
12. Ferguson B, Matyszak MK, Esiri MM & Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain, 120, 393-9
13. Filippi M, Rovaris M, Iannucci G. Mennea S, Sormani MP & Comi G (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55, 1714-18
14. Filippini G, Munari L, Incorvaia B, Ebers GC, Polman C, D'Amico R, & Rice GP (2003). Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet, 361, 545-52
15. Hartung HP, Gonsette R, Konig N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a plaebo-controlled, double-bling, randomised, multicentre trial. Lancet, 360, 2018-25
16. Hern JEC, Downie AW, Pitt M et al (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet, 2, 179-83
17. Jacobs LD, Cookfair DL, Rudick RA et al. (1988) Intramuscular interferon beta- 1a for disease progression in relapsing multiple sclerosis. Annals of Neurology, 39, 285-94
18. Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 45, 1268-76
19. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J & Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain, 125, 2202-12
20. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT & Thompson AJ (2003) Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology, 60, 44-51.
21. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M & Lassmann H (2000) Heterogeneity of multiple sclerosis lesions. implications for the pathogenesis of demyelination. Annals Neurology, 47, 707-17
22. Molyneux PD, Kappos L, Polman C, et al (2000). The effect of interferon beta- 1b treatment of MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta- 1b in scondary progressive multiple slerosis. Brain, 123, 2256-63
23. Noseworthy JH, O'Brien P, Erickson BJ, Lee D, Sneve D, Ebers GC, Rice GP, Auty A, Hader WJ, Kirk A, Duquette P, Carter J, Francis G, Metz L, Shuster E (1998) The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis. Neurology, 51. 1342-52
24. Noseworthy JH, Ebers GC, Gent M et al. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exhancge in progressive multiple sclerosis. Lancet, 337, 441-6
25. Palace J & Rothwell P (1997) New treatments and azathioprine in multiple sclerosis [letter]. Lancet, 350, 261
26. Panitch H, Miller A, Paty D & Weinshenker B (2004) Interferon beta- 1b in secondary progressive MS: results from a 3-year controlled study. Neurology, 63, 1788-95
27. Paty DW & Li DKB (1993) Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology, 43, 662-7
28. PRISMS (2001) Long-term efficacy of interferon-beta- 1a in relapsing MS. Neurology, 56, 1628-36
29. Pryce G, Ahmed Z, Hankey DJ et al. (2003) Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 126, 2191-202
30. PRISMS (Prevention of Relapses and Disability by Interferon beta- 1a Subcutaneously in Multiple Sclerosis) Study Group. (1998) Randomised double-blind plascebo-controlled study of interferon beta- 1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-504
31. Redford EJ, Kapoor R & Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain, 120, 2149-57
32. Rice GP, Filippi M & Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group Neurology, 54, 1145-55
33. Rudge P, Koetsier JC, Mertin J et al. (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry, 52, 559-65
34. Smith KJ, Kapoor R, Hall SM & Davies M (2001) Electrically active axons degenerate when exposed to nitric oxide. Annals of Neurology, 49, 470-6
35. SPECTRIMS (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology, 56,1496-504
36. Steck AJ, Regli F, Ochsner F & Gauthier G (1990) Cycosporine versus azathioprine in the treatment of multiples sclerosis: 12-month clinical and immunological evaluation. European Neurology, 30, 224-8
37. Sudlow CL & Counsell CE (2003) Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. British Medical Journal, 326, 388-92
38. The CHAMPS Study Group. (2000) Intramuscular interferon beta- 1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl Journal of Medy, 343, 898-904
39. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S & Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl Journal of Medy, 338, 278-85
40. Weiner HL, Mackin GA, Orav EJ et al. (1993) Intermitent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology, 43, 910-8
41. Weinshenker BG, Bass B, Rice GP et al. (1989) The natural history of multiples sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain, 112, 1419-28
42. Wilkins A, Chandran S & Compston A (2001) A role for oligodendrocyte-derived IGF-1 in trophic support of cortical neurons. Gila, 36, 48-57
43. Wolswijk G (1998) Oligodendrocyte regeneration in the adult rodent CNS and the failure of this process in multiple sclerosis. Progress in Brain Research, 117, 233-47
44. Yudkin PL, Ellison GW, Ghezzi A et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338, 1051-5